Focused On-demand Library for Coiled-coil domain-containing protein 32

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BV29

UPID:

CCD32_HUMAN

Alternative names:

Alternative UPACC:

Q9BV29; A8KAL4; Q86TC4; Q8N788; Q8NAR7

Background:

Coiled-coil domain-containing protein 32 plays a pivotal role in cellular processes, including clathrin-mediated endocytosis and ciliogenesis. It is essential for the modulation of the adaptor protein complex 2, influencing the internalization of key molecules like transferrin. This protein is also crucial for proper cephalic development and maintaining the body's left/right axis, highlighting its significance in embryonic development.

Therapeutic significance:

The protein is linked to Cardiofacioneurodevelopmental syndrome, a disorder marked by developmental delays, cardiac defects, and distinctive facial features. Understanding the role of Coiled-coil domain-containing protein 32 could open doors to potential therapeutic strategies for this syndrome, offering hope for targeted interventions.